Azoles are the first-line antifungal agents used for the treatment of Aspergillus infection. There is an increasing concern for azole resistance all over the world mainly from agricultural fungicid...
21 January 2021 in American Journal of Case Reports
We report a 43-year-old male farm worker from El Salvador residing in California's Central Valley who presented with 4 months of progressive upper lip swelling, ulcerative lesions on the nose and left forearm, weight loss, night sweats, headaches, and hoarseness of voice. He had severe HIV-related immunosuppression (CD4 count of 81 cells/mm3). Biopsy of a forearm lesion and endobronchial tissue obtained at bronchoscopy revealed intracellular amastigotes consistent with leishmaniasis. Leishmania PCR on endobronchial tissue detected Leishmania donovani/infantum/chagasi complex, and plasma microbial cell-free DNA testing (Karius) confirmed L. infantum. The patient received intravenous liposomal amphotericin B and restarted on antiretroviral therapy; he was discharged to receive induction and maintenance amphotericin B infusions with outpatient HIV clinic follow-up. This case illustrates the diagnostic challenges of disseminated leishmaniasis in severely immunocompromised patients in nonendemic settings and underscores the importance of early recognition and a tiered diagnostic approach in high-risk populations.
We report the case of a 35-year-old female with advanced HIV diagnosed with a mixed mycotic infection. Diagnosis was assisted by Karius test. She was admitted with postpartum psychosis and developed fever and acute hypoxic respiratory failure initially thought to be from a bacterial hospital-acquired pneumonia. Due to lack of sufficient improvement on appropriate antibiotics, a broad infectious workup was sent. A Karius test was performed early during the workup. It returned positive for Pneumocystis jirovecii, Coccidioides posadasii, and Histoplasma capsulatum. Eventually a standard work up returned with a positive bronchoalveolar lavage (BAL) Pneumocystis jirovecii pneumonia (PJP) test by direct fluorescent antibody (DFA), positive Histoplasma urine antigen, and positive serum coccidioidal titer of 1:16, corroborating the diagnosis of mixed mycotic infection. She was treated with a 21-day course of trimethoprim-sulfamethoxazole followed by primaquine and clindamycin for PJP. She clinically improved with over 3 weeks of IV amphotericin B to cover for histoplasmosis and coccidioidomycosis, which was later de-escalated to oral itraconazole. She was instructed to follow up in clinic where bictegravir/emtricitabine/tenofovir alafenamide was initiated. This case highlights the utility of building a broad differential diagnosis as mixed mycotic infections can coexist in an immunocompromised host, and of utilizing a Karius test early in the course of illness in an immunocompromised patient to expedite a diagnosis. This case also demonstrates the need to recognize the changing geographic distribution of fungal infections.
Fungal infections constitute a large portion of serious infections worldwide and are increasing, partially due to new immunomodulatory therapies, such as Sphingosine-1-Phosphate (S1P) receptor modulators, including fingolimod for the treatment of multiple sclerosis (MS). Fingolimod antagonizes multiple S1P receptors, including S1PR1, S1PR3, S1PR4, and S1PR5, resulting in immunological alterations that may increase susceptibility to invasive fungal infections (IFIs). Our PubMed-based literature search identified 43 published cases and a 60-patient case series describing invasive fungal infections in patients receiving S1P receptor modulators. Of these, cryptococcosis was the most frequently documented infection, followed by histoplasmosis and coccidioidomycosis. Most published cases involved patients on fingolimod, whereas evidence for the other medications in this class is extremely limited. Currently, there are no standardized fungal screening protocols. A baseline complete blood count with differentials should be obtained before the initiation of S1P receptor modulator therapy. Patients should also be monitored clinically for signs and symptoms of fungal infection. Primary antifungal prophylaxis and routine serum cryptococcal antigen testing are not currently recommended. Management of suspected IFIs should focus on diagnostic workup to identify the causative organism and extent of organ involvement to determine the appropriate antifungal therapy. Decisions regarding interruption or discontinuation of MS therapy should be individualized according to the clinical syndrome, infection severity, and risk of MS rebound. This narrative review synthesizes the available mechanistic and clinical evidence on invasive fungal infections in patients with multiple sclerosis receiving S1P receptor modulator therapy.